Beam Therapeutics Executive Compensation Details
Ticker: BEAM · Form: DEF 14A · Filed: Apr 18, 2025
Sentiment: neutral
Topics: executive-compensation, DEF 14A, equity-awards
TL;DR
Beam Therapeutics DEF 14A out: Executive pay details for 2024 are in. Check out equity awards and compensation changes.
AI Summary
Beam Therapeutics Inc. filed its DEF 14A on April 18, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted, outstanding awards, and changes in their reported values, as well as compensation for its principal executive officer and other named executive officers.
Why It Matters
This filing provides transparency into how Beam Therapeutics compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This is a routine filing providing information on executive compensation and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- Beam Therapeutics Inc. (company) — Filer of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for compensation details
- 20250418 (date) — Filing date of the DEF 14A
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide detailed information regarding the compensation of Beam Therapeutics Inc.'s executive officers and directors for the fiscal year ending December 31, 2024.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 18, 2025.
What fiscal year does the compensation information in this filing primarily cover?
The compensation information in this filing primarily covers the fiscal year ending December 31, 2024.
What type of compensation is detailed in the filing?
The filing details various forms of compensation, including information related to equity awards, their grant dates, vesting, and changes in their fair value.
Where is Beam Therapeutics Inc. headquartered?
Beam Therapeutics Inc. is headquartered at 26 Lansdowne Street, Cambridge, MA 02139.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 18, 2025 regarding Beam Therapeutics Inc. (BEAM).